ASST Spedali Civili di Brescia
Brescia, 25123, Italy
Location status: Recruiting
NCT Number: NCT06313333
Collect clinical history and treatment data of AD in adulthood;
Interested in participating?
Request Info18 year and older
All sexes
Observational
Brescia, 25123, Italy
Location status: Recruiting
Atopic dermatitis is a chronic-recurrent inflammatory skin disease with high prevalence in children and frequently presenting clinical remission during or after childhood; however, it may persist and/or recur, even after long and transient remission, adulthood. In addition, in some adult patients, DA is not present in pediatric age, but onset in adulthood: the investigators speak, in these cases, of adult-onset DA. The prevalence of DA is increasing all over the world and the cases in which clinical manifestations appear or persist during adolescence and/or adulthood are increased especially in industrialized countries. are not currently available specific laboratory markers for diagnosis of DA and, therefore, diagnosis is eminently clinical. In fact, at the present time, there are no validated diagnostic criteria, nor is there a clear consensus on diagnostic-therapeutic pathway to be followed when evaluating patients with adult DA. For these reasons, the collection of data related to various aspects of the DA such as those epidemiological, medical and clinical history, as well as the impact of the disease on the quality of life, results of crucial importance for estimating the real prevalence of this disease in Italy and also, possibly, to outline possible diagnostic criteria specific to adult DA, so that to facilitate and improve the diagnostic-therapeutic path of the patient. The intention of the project, therefore, is to create and use a National Register dedicated to DA patients in adulthood regardless of the period of onset of their pathology. aim to place the Italian Register as a supranational reference for international studies conducted on the adult DA.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: from baseline through study completion, an average of 3 year
Reassessment of the epidemiology of AD
Time frame: from baseline through study completion, an average of 3 year
Assessment of treatment profiles and identification of factors that determine the decision about the specific treatment of moderate and severe AD
Time frame: from baseline through study completion, an average of 3 year
Assessment of any comorbidities;
Time frame: from baseline through study completion, an average of 3 year
Outlining possible diagnostic criteria specific to AD in adults;
Time frame: from baseline through study completion, an average of 3 year
Evaluation of the natural history of AD and identification of possible conditioning factors;
Contact information is provided by the study sponsor or research team.
Societa Italiana di Dermatologia Medica, Chirurgica, Estetica e di Malattie Sessualmente Trasmesse
Other
Registro Nazionale Della Dermatite Atopica Moderata e Severa Nell'Adulto
Acronym: ATOPYREG
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07262983
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Bethesda, Maryland, United States
View Trial DetailsNCT04419584
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Hong Kong
View Trial DetailsNCT07467564
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Doha, Qatar
View Trial DetailsNCT07216027
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Northridge, California, United States
View Trial Details